Search filters

List of works by James R Berenson

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

scientific article published on 18 February 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

scientific article

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

scientific article

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

scientific article published in March 2005

Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study

scientific article published on 25 April 2018

Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients

scientific article published on 22 April 2020

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

scientific article published in March 2006

JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression

scientific article published on 18 August 2019

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

scientific article published on 11 December 2013

Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment

scientific article published on 22 May 2020

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia

scientific article published on 01 October 2019

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

scientific article

Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma

scientific article published on 20 December 2020

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.

scientific article published on 21 November 2017

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

scientific article

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

scientific article

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

scientific article

Paulina is supported by:

About Paulina

Help